MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Accounts Receivables 2011-2026 | BMY
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 B | 10.7 B | 10.9 B | 9.89 B | 9.37 B | 8.5 B | 7.68 B | 5.96 B | 6.3 B | 5.54 B | 4.3 B | 3.39 B | 3.36 B | 3.08 B | 3.74 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.4 B | 3.08 B | 6.95 B |
Quarterly Accounts Receivables Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 B | 10.8 B | 11 B | 11.4 B | 10.4 B | 10.3 B | 10.1 B | 10.1 B | 9.89 B | 9.61 B | - | 8.51 B | 9.37 B | 9.24 B | 9.02 B | 8.66 B | 8.5 B | 8.5 B | 8.5 B | 8.5 B | 7.68 B | 7.68 B | 7.68 B | 7.68 B | 5.75 B | 5.96 B | 5.96 B | 5.96 B | 6.3 B | 6.3 B | 6.3 B | 6.3 B | 5.54 B | 5.54 B | 5.54 B | 5.54 B | 4.3 B | 4.3 B | 4.3 B | 4.3 B | 3.39 B | 3.39 B | 3.39 B | 3.39 B | 3.36 B | 3.36 B | 3.36 B | 3.36 B | 3.08 B | 3.08 B | 3.08 B | 3.08 B | 3.74 B | 3.74 B | 3.74 B | 3.74 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.4 B | 3.08 B | 6.49 B |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Axsome Therapeutics
AXSM
|
224 M | $ 163.89 | - | $ 8.15 B |  USA |
 |
BridgeBio Pharma
BBIO
|
139 M | $ 64.28 | -3.31 % | $ 12.3 B | USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
BioCardia
BCDA
|
63 K | $ 1.37 | 5.81 % | $ 29 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 59.8 | -3.13 % | $ 11.5 B | USA |
 |
Benitec Biopharma
BNTC
|
33 K | $ 10.93 | 0.23 % | $ 450 M | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
BioXcel Therapeutics
BTAI
|
131 K | $ 1.63 | -2.4 % | $ 4.13 M | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Catalyst Biosciences
CBIO
|
1.82 M | $ 11.67 | -3.47 % | $ 768 M | USA |
 |
C4 Therapeutics
CCCC
|
2.4 M | $ 3.06 | 13.3 % | $ 254 M | USA |
 |
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | USA |
 |
Codexis
CDXS
|
25 M | $ 0.99 | -2.04 % | $ 72.7 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
1 M | - | 17.91 % | $ 11.1 M | USA |